Navigation Links
NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets

a-under-the-curve/AUC(0-inf)). These results will be used to support NovaDel's NDA submission this year. In addition, NovaDel also conducted assessments on the speed of drug absorption to attain therapeutic drug levels and an assessment of sedation. These results will not be used by NovaDel for its NDA submission.

Results of the Studies & Data to Support NDA Submission

NVD003 Study - Healthy volunteers

Pursuant to FDA guidance in this type of crossover study, all data were compared to the highest marketed dose, which in this study was the 10 mg Ambien(R) tablet. This dose therefore served as the primary standard of reference in this analysis. Confidence intervals (CI) for Cmax and AUC were required to be greater than 0.8 and less than 1.25 in order for zolpidem oral spray to achieve comparability against the 10 mg Ambien(R) tablet, the primary standard.

-- The NVD003 study provided definitive results in favor of 10 mg zolpidem oral spray based on the parameters of Cmax (CI = 0.839 - 1.070) and AUC(0-inf) (CI: 0.846 - 1.072). NovaDel's 10 mg and 5 mg oral sprays achieved bioequivalence with 10 mg Ambien(R) tablets, the primary standard of reference for this study. The 5 mg oral spray narrowly missed bioequivalence with the 5 mg Ambien(R) tablet achieving AUC(0-inf) (CI: 0.794 - 1.006). Further analysis revealed that 5 mg Ambien(R) tablets (when dose normalized) were not bioequivalent to 10 mg Ambien(R) tablets. These results suggest that two 5 mg Ambien(R) tablets could yield a higher plasma level than a single 10 mg Ambien(R) tablet.

NVD004 Study - Elderly, healthy volunteers

-- The NVD004 study provided definitive results in favor of 5 mg zolpidem oral spray based on the parameters of Cmax (CI: 0.922 - 1.157) and AUC(0-inf) (CI: 0.968 - 1.189). These results demonstrate that NovaDel's 5 mg oral spray was bioequivalent to the 5 mg Ambien(R) tablet.

Additional PK Assessment: Time to Reach Therapeutic Levels


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... volunteer enrollment in its Phase II clinical trial for ... study,are expected to be available in early 2009., ... 210,adolescents, between the ages of 12 to 17, who ...
... Set for Sept. 29, LA JOLLA, Calif., ... ) today announced that data presented at the ... showed that, in,addition to meeting the primary endpoint ... lead AMPA/kainate-type glutamate receptor antagonist,tezampanel, demonstrated improvement on ...
Cached Medicine Technology:Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine 2Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine 3Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert ... International and InHealth media is a global sales and communications firm that offers U.S. ... to continue our business relationship with Mr. Reid Eckert, as his interpretation of the ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... Falls Church, VA (PRWEB) , ... August 30, ... ... Practices, **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... it's much more than a simple digital handwritten signature. , Clinical ...
(Date:8/29/2015)... ... August 29, 2015 , ... It can be ... against dribbled urine and sweat. "In order to prevent these problems, I conceived ... ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It ...
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available ... $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, the public ... regardless of the item’s selling price.” , With competitive pricing in the e-commerce market ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Corporation,(CRM:TSX-V) announced today that it has opened a Center ... the Company,s second in the,Miami area, one of many ... of the Pembroke Pines Center brings the Company,s total ... Institute of Health, the prevalence rate of,hemorrhoids in the ...
... C-Span did to open,the door on Congressional proceedings ... is doing for medical professionals via its live,coverage ... Today is the innovative source of medical news ... credit to,physicians and other clinicians., From March ...
... The Bill & Melinda Gates Foundation,announced today that ... first,round of Grand Challenges Explorations, a US$100 million ... Proposals will,be accepted online at http://www.gcgh.org/explorations ... to submit a proposal by May 15,2008., ...
... Softgel Supplements Formulated for Easy Swallowing and ... ... Many things in life are,hard to swallow, but your vitamins shouldn,t ... a new,way to fuel the body with a complete product line ...
... to reach out to,wounded soldiers, Retired Army Reserve Lieutenant ... uplifting and rejuvenating weekend,retreats -- offered at no cost ... and relaxation for soldiers hurt in Iraq and Afghanistan., ... Terrorists,these brave men and women are now embarking on ...
... 2008) Real-world use of a novel drug-eluting stent ... clinical outcomes, according to one-year data from a large ... on the sirolimus-eluting Excel stent, are being reported today ... Annual Scientific Sessions in Partnership with ACC i2 Summit ...
Cached Medicine News:Health News:CRH Medical Corporation opens new center in Pembroke Pines Florida 2Health News:MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences 2Health News:Gates Foundation Now Accepting Proposals for Grand Challenges Explorations 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 3Health News:Healing Wounds and Hearts: Warrior Weekend Helps Soldiers Relax and Recover 2Health News:Registry unveils 'real-world' data on novel excel stent 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B1 Biological Safety Cabinet...
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
Medicine Products: